SCHEDULE: Dauntless Investment Group Discloses OKYO Pharma Stake
Beneficial Ownership Disclosure
Dauntless Investment Group, LLC has disclosed a 7.3% passive ownership stake in OKYO Pharma Ltd, holding 2,735,780 common shares.
Summary
- Dauntless Investment Group, LLC reported beneficial ownership of 2,735,780 common shares of OKYO Pharma Ltd.
- This represents 7.3% of OKYO Pharma Ltd's common stock.
- Dauntless Investment Group, LLC is classified as a Single Family Office/Passive Investor.
- Dauntless Investment Group, LLC holds sole dispositive power over 539,961 shares and shared dispositive power over 2,195,819 shares.
- No sole or shared voting power is held over these shares.
- The securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or outlook. It is a neutral regulatory requirement.
Positives
- A significant passive investment by Dauntless Investment Group, LLC could be interpreted as a vote of confidence in OKYO Pharma Ltd's long-term prospects.
- The filing explicitly states the investment is passive, indicating no immediate intent to influence company control.
Risks
- The filing itself does not detail specific risks related to OKYO Pharma Ltd's operations or financial health, as it is a disclosure of ownership.
Industry Context
This filing represents a standard disclosure of a significant passive ownership stake, common among institutional investors or family offices that acquire more than 5% of a company's shares without intending to exert control. It provides transparency regarding major shareholders in the market.
Stakeholder Impact
- Shareholders: Provides transparency on a significant passive investor, potentially influencing market perception of the stock.
- Management: Awareness of a new significant passive shareholder.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement |
Keywords
OKYO Pharma Ltd, Dauntless Investment Group, Beneficial Ownership, Schedule 13G, Passive Investment, Common Stock, SEC Filing, Pharma
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.